Labelled compounds of interest as antitumour agents – VIII. Synthesis of ²H‐isotopomers of pentamethylmelamine and of a potential prodrug thereof

Abstract

Treatment of 2‐chloro‐4,6‐(dimethylamino)‐1,3,5‐triazine with trideuteromethylamine gave 4,6‐(dimethylamino)‐2‐trideuteromethyl‐1,3,5‐triazine, an isotopomer of the experimental anticancer agent pentamethylmelamine (PMM). Mitsunobu coupling with 1,2‐dimethyl‐3‐hydroxymethyl‐5‐methoxy‐indole‐4,7‐dione gave 1,2‐dimethyl‐3‐(N‐(4,6‐bis(dimethylamino)‐1,3,5‐triazin‐2‐yl)‐N‐trideuteromethylaminomethyl)‐5‐methoxyindole‐4,7‐dione. This conjugate is a potential reductively triggered prodrug of PMM. Copyright © 2002 John Wiley & Sons, Ltd.

Indoles as anticancer agents

“…It entered clinics in the 1970s for the treatment of ovarian carcinoma but difficulties were encountered, as it was insoluble in water and thus is difficult to formulate. However, it has recently been recognised as a second-line treatment for ovarian carcinoma [12][13][14][15][16][17][18][19][102][103][104] . Schoentjes et al [105] reported a patent of indole derivatives with general formula (I) in 2011 and reported its use for the treatment of cancers ( Figure 11).…”